Iqvia Acquires Discovery Services Assets from Charles River Laboratories
Iqvia (IQV) announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories (CRL). These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Methodologies and a small molecule AI platform, designed to accelerate discovery programs and support growing demand for non-animal research methods. The transaction is expected to close in the second quarter.